Sergio Huerta, MD
Addiction Medicine · Albuquerque, NMNPI 1891085882
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $3,278 of the $5,456 with a category attached, or 60.1%. MDD US Operations, LLC accounts for 60.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $3,537 and has fallen 85.1% since, to $525 in 2025.
Across 93 payments — averaging $58.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$3K
- Indivior Inc.$479
- Braeburn Inc.$418
- AstraZeneca$357
- Lilly USA, LLC$265
- Gilead$205
- plus $454 from 11 others
What the payments were for
- Food & beverage$2,15740%
- Education$220%
- Gifts$3,27860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 2 | $3,278 |
| Indivior Inc. | 18 | $479 |
| Braeburn Inc. | 12 | $418 |
| AstraZeneca | 17 | $357 |
| Lilly USA, LLC | 18 | $265 |
| Gilead | 2 | $205 |
| Boehringer Ingelheim | 7 | $150 |
| USWM, LLC | 3 | $59 |
| Amarin Pharma, Inc. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Novo Nordisk | 2 | $34 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Organon | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few addiction medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 50 | $5,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $5,61250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other addiction medicine in Albuquerque
- Laura AllenAlbuquerque$1K
- Sher Ali KhanAlbuquerque$158
- John SimsonAlbuquerque$135
- Patricia PadeAlbuquerque$82
- Florian BirkmayerAlbuquerque$56
- Eileen BarrettAlbuquerque$32
- Colin SevareidAlbuquerque$32
- Margaret FoxEspanola$400
- Chibuzo UkaegbuLas Cruces$70
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.